Immunogenomic classification of hepatocellular carcinoma patients for immune check-point inhibitors therapy: cui bono? | Gut

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via BSG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Article metrics

Commentary

Immunogenomic classification of hepatocellular carcinoma patients for immune check-point inhibitors therapy: cui bono?

Online download statistics by month:

Online download statistics by month: April 2022 to March 2024

	Abstract	Full	Pdf
Apr 2022	394	18	7
May 2022	1089	56	24
Jun 2022	733	38	8
Jul 2022	309	23	11
Aug 2022	287	9	1
Sep 2022	278	21	3
Oct 2022	261	29	2
Nov 2022	273	17	6
Dec 2022	746	44	26
Jan 2023	256	35	22
Feb 2023	145	19	15
Mar 2023	269	26	7
Apr 2023	105	12	3
May 2023	65	9	6
Jun 2023	56	9	5
Jul 2023	143	5	5
Aug 2023	1661	13	7
Sep 2023	1948	14	13
Oct 2023	2477	6	1
Nov 2023	2029	14	3
Dec 2023	1504	5	2
Jan 2024	1498	5	1
Feb 2024	1345	5	1
Mar 2024	1495	3	0
Total	19366	435	179